
	November 4, 2008

Now Available:
Watch video podcasts of press conference footage from ACR 2008

CME Meetings:

Musculoskeletal Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, and on-location coverage of medical meetings.

With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

ACR 2008: Visit MSK Report's dedicated ACR 2008 page
for complete coverage of the American College of Rheumatology's Annual Scientific Meeting, including press conference videos and interviews with presenters.

ACR 2008: Tanezumab Reduces Moderate-Severe OA Pain in Phase II Trial
The nerve-growth-factor blocker tanezumab given once every 8 weeks significantly reduced knee OA pain in a phase 2 trial...

ACR 2008: Fibromyalgia Dopamine Agonist Treatment Linked to Compulsive Behaviors
The dopamine agonist pramipexole used to treat fibromyalgia is suspected of causing some of the same compulsive behaviors seen in Parkinson¡¯s disease patients who take this drug...

Pain: Overnight Femoral Nerve Block As Good As 4-Day Block for Knee Replacement Pain
An overnight femoral nerve block improves function as well as a 4-day continuous femoral nerve block following total knee arthroplasty, although the continuous femoral nerve block may offer other advantages...

BioPharm Business: Genentech, Biogen Idec Rituxan Phase III Data in RA Patients Showed Patients who Received Fixed Interval Re-Treatment Maintained Treatment Response; Positive Phase III Data Also Reported for Rituxan plus MTX in Biologic-Naïve RA Patients, Immune Response in Rituxan-Treated Patients Yielded Mixed Results in Phase II Study
Rituxan, in combination with MTX, is indicated to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies...